Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.47 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | YARS1 | P54577 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5904162 | 1.00 | FOLH1 (0.47) | FOLH1NAALAD2ATMKMT2ACA12 | |
| SCHEMBL5995942 | 1.00 | FOLH1 (0.47) | FOLH1NAALAD2ATMKMT2ACA12 | |
| SCHEMBL6129097 | 1.00 | FOLH1 (0.47) | FOLH1NAALAD2ATMKMT2ACA12 | |
| SCHEMBL10993025 | 0.99 | FOLH1 (0.46) | FOLH1NAALAD2ATMKMT2ACA12 | |
| SCHEMBL11005153 | 0.99 | FOLH1 (0.46) | FOLH1NAALAD2ATMKMT2ACA12 | |
| SCHEMBL8680647 | 0.88 | ATM (0.46) | NAALAD2ATMKMT2ACA1CA2 | |
| SCHEMBL10852869 | 0.88 | ATM (0.46) | NAALAD2ATMKMT2ACA1CA2 | |
| SCHEMBL9302331 | 0.88 | ATM (0.46) | NAALAD2ATMKMT2ACA1CA2 | |
| SCHEMBL11226776 | 0.87 | CA1 (0.40) | FOLH1NAALAD2KMT2ACA12CA1 | |
| SCHEMBL9302453 | 0.87 | CA1 (0.40) | FOLH1NAALAD2KMT2ACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629482-B2 | Process for preparation of cefprozil intermediate | HETERO DRUGS LIMITED (IN) | 2009-12-08 | — | — | US | claimed |
| US-20090048460-A1 | NOVEL PROCESS FOR PREPARATION OF CEFPROZIL INTERMEDIATE | HETERO DRUGS LIMITED | 2009-02-19 | — | — | US | claimed |
| US-20080281093-A1 | Novel Process For Preparation of Cefprozil Intermediate | HETERO DRUGS LIMITED (IN) | 2008-11-13 | — | — | US | claimed |
| EP-2213676-A1 | A Novel process for preparation of cefprozil | Hetero Drugs Limited (IN) | 2010-08-04 | — | — | EP | disclosed |
| EP-1809638-B1 | A NOVEL PROCESS FOR PREPARATION OF CEFPROZIL INTERMEDIATE | HETERO DRUGS LTD (IN) | 2010-02-17 | — | — | EP | disclosed |
| US-7629482-B2 | Process for preparation of cefprozil intermediate | HETERO DRUGS LIMITED (IN) | 2009-12-08 | — | — | US | disclosed |
| US-20090048460-A1 | NOVEL PROCESS FOR PREPARATION OF CEFPROZIL INTERMEDIATE | HETERO DRUGS LIMITED | 2009-02-19 | — | — | US | disclosed |
| US-20080281093-A1 | Novel Process For Preparation of Cefprozil Intermediate | HETERO DRUGS LIMITED (IN) | 2008-11-13 | — | — | US | disclosed |
| US-20080281093-A1 | Novel Process For Preparation of Cefprozil Intermediate | HETERO DRUGS LIMITED (IN) | 2008-11-13 | — | — | US | disclosed |
| EP-1809638-A1 | A NOVEL PROCESS FOR PREPARATION OF CEFPROZIL INTERMEDIATE | Hetero Drugs Limited (IN) | 2007-07-25 | — | — | EP | disclosed |
| US-20060223789-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | NABRIVA THERAPEUTICS AG (AT) | 2006-10-05 | — | — | US | disclosed |
| WO-2006048887-A1 | A NOVEL PROCESS FOR PREPARATION OF CEFPROZIL INTERMEDIATE | HETERO DRUGS LIMITED (IN) | 2006-05-11 | — | — | WO | disclosed |
| US-20040132709-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | ASCHER GERD (AT) | 2004-07-08 | — | — | US | disclosed |
| US-6693095-B2 | 7-(((5-AMINO-1,2,4-THIADIAZOL-3-YL)-(Z)-(FLUORMETHOXYIMINO) -ACETYL)AMINO)-3(E)-((IMINO-1-PIPERAZINYLMETHYL)-METHYLHYDRAZONO)METHYL-3 -CEPHEM-4-CARBOXYLIC ACID TRIHYDROCHLORIDE FOR EXAMPLE | BIOCHEMIE GESELLSCHAFT M.B.H. (AT) | 2004-02-17 | — | — | US | disclosed |
| US-20030114665-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | ASCHER GERD (AT) | 2003-06-19 | — | — | US | disclosed |
| EP-1300408-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono)methyl-cephalosporins and intermediates | BIOCHEMIE Gesellschaft m.b.H. (AT) | 2003-04-09 | — | — | EP | disclosed |
| US-20020115852-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | ASCHER GERD (AT) | 2002-08-22 | — | — | US | disclosed |
| US-20020091252-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | NABRIVA THERAPEUTICS AG (AT) | 2002-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114665-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | MRPL21, Q6ZSR9, EMG1 | FOLH1 3585/4885NAALAD2 32/4885ATM 3238/4885 |
| US-20080281093-A1 | Novel Process For Preparation of Cefprozil Intermediate | PTMA, PCMT1, CYP4Z1 | FOLH1 2010/4885NAALAD2 54/4885ATM 3369/4885 |
| US-20020115852-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | MRPL21, Q6ZSR9, EMG1 | FOLH1 3585/4885NAALAD2 32/4885ATM 3238/4885 |
| US-20090048460-A1 | NOVEL PROCESS FOR PREPARATION OF CEFPROZIL INTERMEDIATE | PTMA, PCMT1, CYP4Z1 | FOLH1 2010/4885NAALAD2 54/4885ATM 3369/4885 |
| US-20020091252-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | MRPL21, Q6ZSR9, EMG1 | FOLH1 3585/4885NAALAD2 32/4885ATM 3238/4885 |
| US-20060223789-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | MRPL21, Q6ZSR9, PRMT7 | FOLH1 4044/4885NAALAD2 57/4885ATM 1948/4885 |
| US-20040132709-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | MRPL21, Q6ZSR9, EMG1 | FOLH1 3585/4885NAALAD2 32/4885ATM 3238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.